Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population

David Bangsberg, Frederick M. Hecht, Edwin D. Charlebois, Andrew R. Zolopa, Mark Holodniy, Lewis Sheiner, Joshua D. Bamberger, Margaret A. Chesney, Andrew Moss

Research output: Contribution to journalArticle

816 Citations (Scopus)

Abstract

Objective: To examine the relationship between adherence, viral suppression and antiretroviral resistance in HIV-infected homeless and marginally housed people on protease inhibitor (PI) therapy. Design and setting: A cross-sectional analysis of subjects in an observational prospective cohort systematically sampled from free meal lines, homeless shelters and low-income, single-room occupancy (SRO) hotels. Participants: Thirty-four HIV-infected people with a median of 12 months of PI therapy. Main outcomes: Adherence measured by periodic unannounced pill counts, electronic medication monitoring, and self-report; HIV RNA viral load; and HIV-1 genotypic changes associated with drug resistance. Results: Median adherence was 89, 73, and 67% by self-report, pill count, and electronic medication monitor, respectively. Thirty-eight per cent of the population had over 90% adherence by pill count. Depending on the measure, adherence explained 36-65% of the variation in concurrent HIV RNA levels. The three adherence measures were closely related. Of 20 genotyped patients who received a new reverse transcriptase inhibitor (RTI) when starting a PI, three had primary protease gene substitutions. Of 12 genotyped patients who received a PI without a new RTI, six had primary protease gene substitutions (P < 0.03). Conclusion: A substantial proportion of homeless and marginally housed individuals had good adherence to PI therapy. A strong relationship was found between independent methods of measuring adherence and concurrent viral suppression. PI resistance was more closely related to the failure to change RTI when starting a PI than to the level of adherence. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
Pages (from-to)357-366
Number of pages10
JournalAIDS
Volume14
Issue number4
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

HIV Protease Inhibitors
Poverty
Protease Inhibitors
Viral Load
Drug Resistance
Reverse Transcriptase Inhibitors
Population
HIV
Self Report
Peptide Hydrolases
RNA
Human immunodeficiency virus 1 p16 protease
Genes
Meals
HIV-1
Therapeutics
Cross-Sectional Studies

Keywords

  • Access to therapy
  • Adherence
  • Highly active antiretroviral therapy
  • HIV
  • Homeless
  • Injection drug use
  • Protease inhibitor
  • Resistance
  • Viral load

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Bangsberg, D., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., ... Moss, A. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14(4), 357-366. https://doi.org/10.1097/00002030-200003100-00008

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. / Bangsberg, David; Hecht, Frederick M.; Charlebois, Edwin D.; Zolopa, Andrew R.; Holodniy, Mark; Sheiner, Lewis; Bamberger, Joshua D.; Chesney, Margaret A.; Moss, Andrew.

In: AIDS, Vol. 14, No. 4, 2000, p. 357-366.

Research output: Contribution to journalArticle

Bangsberg, D, Hecht, FM, Charlebois, ED, Zolopa, AR, Holodniy, M, Sheiner, L, Bamberger, JD, Chesney, MA & Moss, A 2000, 'Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population', AIDS, vol. 14, no. 4, pp. 357-366. https://doi.org/10.1097/00002030-200003100-00008
Bangsberg, David ; Hecht, Frederick M. ; Charlebois, Edwin D. ; Zolopa, Andrew R. ; Holodniy, Mark ; Sheiner, Lewis ; Bamberger, Joshua D. ; Chesney, Margaret A. ; Moss, Andrew. / Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. In: AIDS. 2000 ; Vol. 14, No. 4. pp. 357-366.
@article{d935e214e95f4900beaa92bc97c4bf3d,
title = "Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population",
abstract = "Objective: To examine the relationship between adherence, viral suppression and antiretroviral resistance in HIV-infected homeless and marginally housed people on protease inhibitor (PI) therapy. Design and setting: A cross-sectional analysis of subjects in an observational prospective cohort systematically sampled from free meal lines, homeless shelters and low-income, single-room occupancy (SRO) hotels. Participants: Thirty-four HIV-infected people with a median of 12 months of PI therapy. Main outcomes: Adherence measured by periodic unannounced pill counts, electronic medication monitoring, and self-report; HIV RNA viral load; and HIV-1 genotypic changes associated with drug resistance. Results: Median adherence was 89, 73, and 67{\%} by self-report, pill count, and electronic medication monitor, respectively. Thirty-eight per cent of the population had over 90{\%} adherence by pill count. Depending on the measure, adherence explained 36-65{\%} of the variation in concurrent HIV RNA levels. The three adherence measures were closely related. Of 20 genotyped patients who received a new reverse transcriptase inhibitor (RTI) when starting a PI, three had primary protease gene substitutions. Of 12 genotyped patients who received a PI without a new RTI, six had primary protease gene substitutions (P < 0.03). Conclusion: A substantial proportion of homeless and marginally housed individuals had good adherence to PI therapy. A strong relationship was found between independent methods of measuring adherence and concurrent viral suppression. PI resistance was more closely related to the failure to change RTI when starting a PI than to the level of adherence. (C) 2000 Lippincott Williams and Wilkins.",
keywords = "Access to therapy, Adherence, Highly active antiretroviral therapy, HIV, Homeless, Injection drug use, Protease inhibitor, Resistance, Viral load",
author = "David Bangsberg and Hecht, {Frederick M.} and Charlebois, {Edwin D.} and Zolopa, {Andrew R.} and Mark Holodniy and Lewis Sheiner and Bamberger, {Joshua D.} and Chesney, {Margaret A.} and Andrew Moss",
year = "2000",
doi = "10.1097/00002030-200003100-00008",
language = "English (US)",
volume = "14",
pages = "357--366",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population

AU - Bangsberg, David

AU - Hecht, Frederick M.

AU - Charlebois, Edwin D.

AU - Zolopa, Andrew R.

AU - Holodniy, Mark

AU - Sheiner, Lewis

AU - Bamberger, Joshua D.

AU - Chesney, Margaret A.

AU - Moss, Andrew

PY - 2000

Y1 - 2000

N2 - Objective: To examine the relationship between adherence, viral suppression and antiretroviral resistance in HIV-infected homeless and marginally housed people on protease inhibitor (PI) therapy. Design and setting: A cross-sectional analysis of subjects in an observational prospective cohort systematically sampled from free meal lines, homeless shelters and low-income, single-room occupancy (SRO) hotels. Participants: Thirty-four HIV-infected people with a median of 12 months of PI therapy. Main outcomes: Adherence measured by periodic unannounced pill counts, electronic medication monitoring, and self-report; HIV RNA viral load; and HIV-1 genotypic changes associated with drug resistance. Results: Median adherence was 89, 73, and 67% by self-report, pill count, and electronic medication monitor, respectively. Thirty-eight per cent of the population had over 90% adherence by pill count. Depending on the measure, adherence explained 36-65% of the variation in concurrent HIV RNA levels. The three adherence measures were closely related. Of 20 genotyped patients who received a new reverse transcriptase inhibitor (RTI) when starting a PI, three had primary protease gene substitutions. Of 12 genotyped patients who received a PI without a new RTI, six had primary protease gene substitutions (P < 0.03). Conclusion: A substantial proportion of homeless and marginally housed individuals had good adherence to PI therapy. A strong relationship was found between independent methods of measuring adherence and concurrent viral suppression. PI resistance was more closely related to the failure to change RTI when starting a PI than to the level of adherence. (C) 2000 Lippincott Williams and Wilkins.

AB - Objective: To examine the relationship between adherence, viral suppression and antiretroviral resistance in HIV-infected homeless and marginally housed people on protease inhibitor (PI) therapy. Design and setting: A cross-sectional analysis of subjects in an observational prospective cohort systematically sampled from free meal lines, homeless shelters and low-income, single-room occupancy (SRO) hotels. Participants: Thirty-four HIV-infected people with a median of 12 months of PI therapy. Main outcomes: Adherence measured by periodic unannounced pill counts, electronic medication monitoring, and self-report; HIV RNA viral load; and HIV-1 genotypic changes associated with drug resistance. Results: Median adherence was 89, 73, and 67% by self-report, pill count, and electronic medication monitor, respectively. Thirty-eight per cent of the population had over 90% adherence by pill count. Depending on the measure, adherence explained 36-65% of the variation in concurrent HIV RNA levels. The three adherence measures were closely related. Of 20 genotyped patients who received a new reverse transcriptase inhibitor (RTI) when starting a PI, three had primary protease gene substitutions. Of 12 genotyped patients who received a PI without a new RTI, six had primary protease gene substitutions (P < 0.03). Conclusion: A substantial proportion of homeless and marginally housed individuals had good adherence to PI therapy. A strong relationship was found between independent methods of measuring adherence and concurrent viral suppression. PI resistance was more closely related to the failure to change RTI when starting a PI than to the level of adherence. (C) 2000 Lippincott Williams and Wilkins.

KW - Access to therapy

KW - Adherence

KW - Highly active antiretroviral therapy

KW - HIV

KW - Homeless

KW - Injection drug use

KW - Protease inhibitor

KW - Resistance

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=0034027217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034027217&partnerID=8YFLogxK

U2 - 10.1097/00002030-200003100-00008

DO - 10.1097/00002030-200003100-00008

M3 - Article

C2 - 10770537

AN - SCOPUS:0034027217

VL - 14

SP - 357

EP - 366

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 4

ER -